PT-141 (Bremelanotide): RECONNECT Trial Data, Who It Works For, and What the Cardiovascular Warning Means

What Is PT-141?

PT-141, now known generically as bremelanotide, didn’t start life as a sexual function drug. It emerged from research into sunless tanning agents in the 1980s and 1990s, when scientists were exploring analogs of alpha-melanocyte-stimulating hormone (alpha-MSH) — a naturally occurring melanocortin peptide that stimulates melanin production in skin. The parent compound in that research, Melanotan II, produced the anticipated skin-darkening effect in early human trials. What researchers didn’t expect was the frequency with which male trial participants reported spontaneous erections. That side effect redirected a significant amount of research attention toward sexual function.

PT-141 is a cyclic heptapeptide derived from that lineage. Its precise chemical sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH — a synthetic structural analog of alpha-MSH engineered to retain melanocortin receptor binding while reducing some of the peripheral effects of the parent compound. The result was bremelanotide, developed by Palatin Technologies and eventually licensed to AMAG Pharmaceuticals.

The FDA approved bremelanotide in June 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the second drug approved for this indication, after flibanserin (Addyi, approved 2015). The formulation is a single-use subcutaneous auto-injector, 1.75 mg, taken approximately 45 minutes before anticipated sexual activity on an as-needed basis — not a daily medication.

The fundamental distinction between PT-141 and every other drug used for sexual dysfunction is where in the body it acts. PDE5 inhibitors like sildenafil and tadalafil work peripherally — on vascular smooth muscle in genital tissue, increasing blood flow via nitric oxide/cGMP pathways. They address the physiological plumbing of arousal but don’t touch desire. Bremelanotide works centrally, in the brain, through melanocortin receptor activation in the hypothalamus. It targets the motivational and desire component of sexual function, not the vascular component.

---

The Mechanism: Central MC4R Agonism

Bremelanotide is a nonselective melanocortin receptor agonist, meaning it can bind multiple receptor subtypes in the melanocortin family (MC1R through MC5R). Its relevant pharmacological activity is concentrated at MC3R and MC4R, with highest functional activity at MC4R.

MC4R is distributed throughout the central nervous system but is particularly dense in the hypothalamus — specifically in the paraventricular nucleus (PVN) and the medial preoptic area (mPOA), two regions with well-established roles in regulating sexual motivation and arousal in multiple species, including humans. MC4R activation in these areas increases dopaminergic neurotransmission and engages the mesolimbic reward pathway. This is the mechanistic explanation for why bremelanotide increases desire (a motivational, reward-seeking state) rather than simply arousal (a physiological response). The target is upstream of the physical response.

This distinction separates bremelanotide mechanistically from flibanserin (Addyi), the other FDA-approved HSDD drug. Flibanserin works primarily through serotonin receptor antagonism (5-HT2A) and dopamine agonism (D4) in the prefrontal cortex — a different set of circuits, a different conceptual model of desire dysregulation. The two drugs have never been compared head-to-head in an RCT. A clinician choosing between them has no direct comparative efficacy data — only mechanistic theory and population characteristics.

The peripheral melanocortin receptor activity of bremelanotide explains most of its side effect profile. MC1R activation in melanocytes produces the transient skin flushing and, with repeated use, hyperpigmentation — particularly in the face, breasts, and genitalia — that is among the drug’s listed side effects. MC3R activation in the hypothalamus and arcuate nucleus, where melanocortin signaling intersects with autonomic control of gastric motility, explains the nausea that affects a meaningful fraction of patients. And peripheral MC1R and MC3R activity on vascular smooth muscle contributes to the transient blood pressure elevation that carries the drug’s most important safety warning — covered in detail below.

---

The RECONNECT Trials: What the Data Actually Shows

The FDA approval was based on two identical Phase III randomized, double-blind, placebo-controlled trials, designated RECONNECT Study 1 and RECONNECT Study 2. Both enrolled premenopausal women with a specific diagnostic profile: generalized acquired HSDD — meaning the onset occurred after a period of normal sexual desire, and the condition was present across all partners and situations, not tied to a specific relationship dynamic or circumstance. This population specificity matters for interpreting who the drug is actually approved to treat.

The treatment arm received bremelanotide 1.75 mg subcutaneously (via the single-dose auto-injector, applied to the abdomen or thigh) approximately 45 minutes before anticipated sexual activity. Dosing was as-needed — not daily or scheduled. The trial ran for 24 weeks.

Two co-primary endpoints were pre-specified:

1. Change from baseline in Female Sexual Function Index-Desire domain (FSFI-D) score — a validated self-report instrument measuring desire frequency, desire level, and confidence in sexual desire on a 6-point scale.
2. Change from baseline in Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score — which specifically measures distress attributable to low sexual desire.

Both RECONNECT Study 1 and Study 2 met both co-primary endpoints: statistically significant improvements in desire score and distress score compared to placebo.

The effect sizes, however, deserve honest examination. FSFI-D improved approximately 0.5–0.7 points over placebo. FSDS-DAO Item 13 improved approximately 0.3–0.4 points over placebo. These differences are statistically significant — both studies were adequately powered to detect them. But “statistically significant” is not the same as “clinically transformative.”

The FDA had established a minimum meaningful improvement threshold: approximately 1.2 points on the FSFI-D and 1.0 points on the FSDS-DAO. Against these thresholds, the meaningful-responder analysis showed approximately 25% of bremelanotide patients meeting the threshold for meaningful benefit, compared to approximately 17% of placebo patients. A real separation — but the honest framing is that most patients (roughly 75%) in the treated group did not meet the threshold for what the FDA considered a meaningful improvement.

The number of satisfying sexual events (SSEs) — a secondary endpoint — showed the bremelanotide group averaging approximately 0.7 more SSEs per month than placebo. For a patient averaging 2–3 SSEs per month at baseline, that’s a meaningful increment. For a patient averaging 0–1, it may shift the pattern materially. Context matters.

---

What the RECONNECT Trials Don’t Tell Us

The enrollment criteria define the boundaries of what the data can claim. Several limitations deserve explicit statement:

Lifelong HSDD was excluded. Both RECONNECT trials enrolled women with acquired HSDD — onset after a period of normal desire. Lifelong HSDD, which may have different neurobiological underpinnings, was not studied. The approval does not extend to lifelong HSDD, and there is no trial data to support use in that population.

Postmenopausal women were excluded entirely. HSDD is arguably more prevalent in postmenopausal women, where hormonal shifts create well-documented changes in sexual desire. The FDA approval is explicitly limited to premenopausal women. No adequately powered trials exist for postmenopausal populations. Off-label use in this group has no RCT foundation.

Men were not included in any trial. Off-label use of PT-141/bremelanotide in men for libido enhancement and erectile function is widespread, particularly in the peptide/functional medicine space. The entire RECONNECT trial program enrolled women only. There is no RCT evidence supporting use in men for any indication.

Placebo response is structurally high in HSDD research. Sexual function trials are notoriously susceptible to placebo effects — attention, expectation, and permission to prioritize sexual wellbeing all drive placebo response. The ~17% meaningful-responder rate in the placebo arm is a reminder of this. The true drug-specific effect is the 8–10 percentage point separation, not the absolute 25% responder rate.

No head-to-head comparison with flibanserin exists. Clinicians choosing between the two approved HSDD drugs are doing so without comparative data. Both drugs are approved for the same indication, have different mechanisms, different administration routes (daily oral vs. as-needed SC injection), and different side effect profiles. The choice is currently made on patient preference, tolerability, and clinical judgment — not on superior efficacy data.

---

The Cardiovascular Warning: Who Cannot Use It

This is the most clinically important limitation of bremelanotide and the primary reason patient selection matters.

Bremelanotide causes a transient, dose-related elevation in blood pressure. In the Phase III trials, the mean increase was approximately +6 mmHg systolic and +3 mmHg diastolic, peaking approximately 4 hours after dosing and resolving within 12 hours. This is not a trivial effect for patients who are not at baseline normotensive.

The mechanism is peripheral melanocortin receptor activation on vascular smooth muscle — distinct from and independent of the central MC4R activity that produces the desired effect on desire. The two effects are pharmacologically linked because they arise from the same compound binding the same receptor family in different tissue compartments. You cannot separate the central effect from the peripheral cardiovascular effect with the current molecule.

The FDA label carries a clear contraindication: patients with known cardiovascular disease or uncontrolled hypertension should not use bremelanotide. This is not a relative caution — it is a contraindication.

Practical clinical implications:

• Blood pressure should be measured before initiating bremelanotide, and patients should be assessed for cardiovascular risk factors.
• Patients should be counseled to report headache, dizziness, or flushing after the first dose — early indicators of a BP response.
• The single-dose auto-injector format (no more than one dose per 24 hours) is in part a consequence of this BP profile.
• Patients who are hypertensive at baseline or who have white-coat hypertension in clinic settings warrant careful individual assessment before prescribing.

The BP elevation, while transient, is real. For patients with controlled hypertension on medication, the risk calculus is not straightforward — there is no trial data specifically in medically controlled hypertensive patients, and prescribers are making that call without guidance.

---

The Off-Label Male Use Question

The pharmacological rationale for male use of PT-141 is not unfounded. MC4R is expressed in the male hypothalamus, and melanocortin signaling in the PVN and mPOA plays a documented role in male sexual arousal regulation in animal models. Several small human studies and case series have explored bremelanotide in psychogenic erectile dysfunction and male hypoactive desire.

But the honest position requires a clear statement: there is no RCT evidence for bremelanotide in men for any indication. The RECONNECT trials enrolled women only. The drug is not approved for men. Off-label use in male patients is physiologically plausible but clinically unevidenced — a meaningful distinction.

Male patients using PT-141 from compounding or research sources are operating on biological plausibility and anecdote. The cardiovascular precautions apply equally regardless of sex — transient BP elevation is a pharmacological property of the compound, not a sex-specific effect.

Any clinician prescribing or discussing PT-141 for male patients should frame the evidence gap explicitly: the mechanism is credible, the trials don’t exist, and the cardiovascular caution is real.

---

Compounded PT-141 vs. Vyleesi

Vyleesi is the FDA-approved formulation: a single-use auto-injector delivering 1.75 mg bremelanotide subcutaneously. The 1.75 mg dose was selected based on pharmacokinetic and pharmacodynamic optimization during Phase II development — it represents the dose used in both RECONNECT trials and the dose for which efficacy and safety data exist.

Compounded bremelanotide is widely available as an injectable powder or reconstituted solution from compounding pharmacies and research chemical sources. Dosing in the compounded context varies: 0.5 mg to 2.0 mg per injection is commonly reported. The compounded preparations do not have FDA-reviewed data on purity, sterility, or stability. Concentration accuracy depends on the compounding pharmacy’s practices and is not subject to the same manufacturing standards as FDA-approved drug products.

There is no clinical trial data comparing the efficacy or safety of compounded bremelanotide formulations to Vyleesi. Patients using compounded PT-141 are using a product outside the evidence base — which may be appropriate in some clinical contexts (cost, access, preference for injectable over auto-injector), but prescribers should communicate that distinction clearly.

The FDA has not approved compounded bremelanotide for human use and has raised concerns about certain compounding practices in this category.

---

Bottom Line

PT-141/bremelanotide is a pharmacologically novel compound with a mechanistically distinct approach to treating sexual desire dysfunction: central MC4R agonism in the hypothalamus targeting desire and motivation, not peripheral vascular effects targeting arousal physiology. That’s a real contribution to the treatment landscape.

The RECONNECT data is real. Both Phase III trials demonstrated statistically significant improvement in both desire scores and sexual distress in premenopausal women with generalized acquired HSDD. But the effect sizes are modest — a 25% vs. 17% meaningful-responder rate is the honest characterization — and the population studied is specific. The drug was not tested in postmenopausal women, lifelong HSDD, or men.

The cardiovascular contraindication is the critical clinical filter. The transient blood pressure elevation is a pharmacological property of the compound, not a rare adverse event. Patients with cardiovascular disease or uncontrolled hypertension are explicitly contraindicated. That rules out a meaningful proportion of the adult population for whom sexual function treatment might otherwise be appropriate.

For the right patient — a premenopausal woman with acquired generalized HSDD, no significant cardiovascular risk factors, whose primary complaint is reduced desire rather than arousal or orgasm dysfunction — bremelanotide is a legitimate, FDA-supported option. The expectation should be calibrated: a meaningful improvement in desire and distress for roughly one in four treated patients, not a transformation of sexual function.

The off-label male use is pharmacologically plausible and clinically unsupported. Any practitioner or patient operating in that space should understand precisely where the evidence ends and the speculation begins. Cardiovascular precautions don’t stop at the approved indication.